MedTrace Logo

TSA-DC Vaccine in Treating Patients With Gastrointestinal Solid Tumor

NCT03185429 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2017-08-14

No results posted yet for this study

Summary

The goal of this study is to learn about the safety and tolerance of autologous TSA-DC cell and evaluate the efficacy and feasibility of the cell therapy compared to the patients' past standard regimen. 20 gastrointestinal solid tumors subjects failed from at least one systemic therapy will be enrolled into the trial and receive a succession of treatment of TSA-DC vaccine.

Conditions

  • Tumor Gastric
  • Tumor, Colorectal

Interventions

BIOLOGICAL

Tumor Specific Antigen-loaded Dendritic Cells

Subjects will be given subcutaneous injection of 5.0x10\^6-1.0x10\^7 TSA-DC on week 1,3,5,11,17,23,35,47.

DRUG

Cyclophosphamide

300 mg/m2 by vein before the first cell infusion.

Sponsors & Collaborators

  • Fujian Cancer Hospital

    collaborator OTHER_GOV

  • BGI, China

    lead OTHER

Principal Investigators

  • ZengQing Guo, Professor · Fujian Cancer Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-31
Primary Completion
2018-12-31
Completion
2019-06-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03185429 on ClinicalTrials.gov